Related Research Articles
Vincent Theodore DeVita Jr. is the Amy and Joseph Perella Professor of Medicine at Yale Cancer Center,and a Professor of Epidemiology and Public Health. He directed the Yale Cancer Center from 1993 to 2003. He has been president of the board of directors of the American Cancer Society (2012-2013). He is internationally recognized as a pioneer in the field of oncology for his work on combination-chemotherapy treatments.
Josep Baselga i Torres,known in Spanish as JoséBaselga,was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents,with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center,Vall d'Hebron Institute of Oncology,and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin,a monoclonal antibody,that targets the HER2 protein,which is impacted in aggressive breast cancers.
David B. Agus is an American physician,cancer researcher and author who serves as a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the Founding Director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. He is also the cofounder of several personalized medicine companies and a contributor to CBS News on health topics. He is also the author of four books.
Olufunmilayo I. Olopade born in the year 1957,is a Nigerian hematology oncologist,Associate Dean for Global Health and Walter L. Palmer,Distinguished Service Professor in Medicine and Human Genetics at the University of Chicago. She also serves as director of the University of Chicago Hospital's Cancer Risk Clinic.
Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He is director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital Yale New Haven Health System,effective February 1,2022. He also is Deputy Dean for Cancer Research at Yale School of Medicine. From 1997 to 2021,he was the Chief of the Breast Oncology Program at Dana–Farber Cancer Institute in Boston,Massachusetts. Beginning in 2013,he held a range of institutional roles at Dana-Farber,including Chief of Clinical Development,the Thompson Chair in Breast Cancer Research and Director of the Dana-Farber/Harvard SPORE in Breast Cancer. He also served as a Professor of Medicine at Harvard Medical School. He was president of the American Society of Clinical Oncology (ASCO) 2022-2023 and became Chair of the Board in mid-June 2023. His career has been focused on breast cancer treatment and research.
Edith A. Pérez is a Puerto Rican hematologist-oncologist. She is the Serene M. and Frances C. Durling Professor of Medicine at the Mayo Clinic Alix School of Medicine.
Scott M. Lippman is the former Director of Moores Cancer Center at the University of California,San Diego and current Professor of Medicine at UC San Diego School of Medicine.
Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen),and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine,and has several drugs in development.
Jennifer Rubin Grandis is an American otolaryngologist,focusing in general otolaryngology and clinical and translational research. Her research interests include diagnosis and treatment of head and neck cancer. She is a Full professor at the University of California,San Francisco having previously worked as the UPMC Endowed Chair at University of Pittsburgh.
Steven T. Rosen is the Provost and chief scientific officer of the City of Hope National Medical Center in Duarte,California. In addition to directing City of Hope's Comprehensive Cancer Center,Rosen leads the Beckman Research Institute at City of Hope,and the Irell &Manella Graduate School of Biological Sciences. Previously (1989-2014) Rosen was the director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University,which was awarded comprehensive cancer center status by the National Cancer Institute (NCI) in 1997.
Rebecca D. Jackson was a medical researcher,medical practitioner and professor of endocrinology,diabetes and metabolism. Her research was significant in the understanding and treatment of osteoporosis. She also researches the opioid crisis in Ohio.
Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine,Professor of Pharmacology,Chief of Medical Oncology,and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven,Connecticut.
Reshma Jagsi is an American Radiation oncologist. She is the Lawrence W. Davis Professor and Chair in the Department of Radiation Oncology and Senior Faculty Fellow in the Center for Ethics at Emory University. Overall,she is the author of over 450 published articles in peer-reviewed medical journals and continues scholarly research in three primary areas of interest:breast cancer,bioethics,and gender equity,with the support of grants from the National Institutes of Health (NIH),the Doris Duke Charitable Foundation,and the Susan G. Komen Foundation,for which she serves as a Senior Scholar.
Everett E. Vokes is an American oncologist. He is the John E. Ultmann Professor,chair of the Department of Medicine,and physician-in-chief at the University of Chicago Medical Center. In this role,he pioneered the combination radiation and chemotherapy as first-line treatment for head and neck cancer.
Lori Jo Pierce is an American radiation oncologist and 57th President of the American Society of Clinical Oncology. She is a Full Professor and Vice Provost for Academic and Faculty Affairs at the University of Michigan. Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer,with emphasis on intensity modulated radiotherapy in node positive breast cancer,the use of radiosensitizing agents,and the outcomes of women treated with radiation for breast cancer who are carriers of a BRCA1/2 breast cancer susceptibility gene.
Stephanie Lynn Schutt Graff is an American breast medical oncologist. She is the Director of Breast Oncology at the Lifespan Cancer Institute and an Assistant Professor of Medicine at Alpert Medical School. Previously she was the Director of both the Breast Program and Clinical Research at Sarah Cannon Research Institute at HCA Midwest Health at Sarah Cannon Research Institute and Associate Director of the Breast Cancer Research Program at Sarah Cannon Research Institute.
Maura Lianne Gillison is an American medical oncologist and molecular epidemiologist. She is credited as the first investigator to establish a connection between HPV and oral cancer.
Beth Young Karlan is an American gynecologic oncologist. In 2008,she was named editor-in-chief of the medical journals Gynecologic Oncology and Gynecologic Oncology Reports. In 2012,Karlan was appointed by the White House to serve on the National Cancer Advisory Board,and in 2015,she was elected to the National Academy of Medicine.
William Pao is an oncologist and Executive Vice President and Chief Development Officer of Pfizer. He was previously the head of Pharma Research and Early Development (pRED) at Roche and a professor of medicine at the Vanderbilt University Medical Center. He is best known for his work in molecular oncology and cancer genomics.
Elizabeth R. Plimack is an American medical oncologist. She is a professor in the Department of Hematology/Oncology and Chief of the Division of Genitourinary Medical Oncology at the Fox Chase Cancer Center. In these roles,she researches the treatment of genitourinary malignancies with a focus on bladder and kidney cancers.
References
- ↑ "Barbara Burtness, MD". Yale University. Retrieved March 27, 2022.
- ↑ Ricks, Delthia (May 20, 2002). "Rejected Drug Shows Promise". Newsday. Retrieved March 27, 2022– via newspapers.com.
- ↑ "People in the news". The Philadelphia Inquirer. June 2, 2008. Retrieved March 27, 2022– via newspapers.com.
- ↑ Donahue, Bill (2011). "Best Women's Physicians 2011". Suburban Life. Retrieved March 27, 2022.
- ↑ "83 Temple Physicians Named Best Doctors in America®". Temple University. February 11, 2013. Retrieved March 27, 2022.
- ↑ "Barbara Ann Burtness, MD Appointed at Yale Cancer Center". Yale University. January 10, 2014. Retrieved March 27, 2022.
- ↑ "Conquer Cancer Honors Winners, Nominees of 2018 Women Who Conquer Cancer Mentorship Awards". ASCO. March 30, 2018. Retrieved March 27, 2022.
- ↑ "Over 200 Yale Medicine Physicians Make 2019 'Best Doctors' List". Yale University. June 14, 2019. Retrieved March 27, 2022.
- 1 2 "Barbara Burtness Named Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center". Yale University. June 22, 2021. Retrieved March 27, 2022.
- ↑ "Yale Cancer Center presents Research awards during annual Conclave". Newswire. February 3, 2020. Retrieved March 27, 2022.
- ↑ "Yale Cancer Center Awarded NIH SPORE Grant for Head and Neck Cancer Research". ASCO Post. October 25, 2020. Retrieved March 27, 2022.
- ↑ Sharma, Manas (November 12, 2021). "Stand Up to Cancer announces new cancer research team co-led by Yale professor". Yale Daily News . Retrieved March 27, 2022.
- ↑ "Barbara Burtness, MD, Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital". Yale University. December 1, 2022. Retrieved April 29, 2024.
| International | |
|---|---|
| National | |
| Academics | |
